Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer Released
“We are very encouraged by these results and thrilled by the signs of rapid reduction in Ki-67 and FTV as it demonstrates progress in our effort to develop (Z)-endoxifen as an effective and tolerant neoadjuvant treatment for ER+/HER2- breast cancer patients. This data provides further evidence that (Z)-endoxifen may be able to slow the progression of ER+ breast cancer in the neoadjuvant setting,” said Dr. Steven Quay, Chief Executive Officer of Atossa Therapeutics. “We are honored to have these findings from the I-SPY 2 EOP study of (Z)-endoxifen presented at the inaugural RISE UP conference and commend Dr. Laura Esserman and other members of the Organizing Committee for their focus on reimagining breast cancer prevention and treatment.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
